Aurobindo Pharma’s wholly owned step-down subsidiary -- Aurolife Pharma LLC has received an establishment inspection report (EIR) for its plant situated at Raleigh, North Carolina, USA , mentioning the inspection a voluntary action initiated (VAI) from the United States Food and Drug Administration (US FDA) and with this, the USFDA pre-approval inspection and GMP inspection are concluded.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
